GlassScriptPhysician profile
Meera B Chitlur
NPI 1952341844
$235,503.12
in general payments reported to CMS, 2019-2025
26 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $32K · 2021: $28K · 2022: $24K · 2023: $4,472 · 2024: $33K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Honoraria: $10K · Travel and Lodging: $8,334 · Food and Beverage: $3,468 · Education: $77.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,666.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,774.26 |
| Honoraria | $10,000.00 |
| Travel and Lodging | $8,334.34 |
| Food and Beverage | $3,468.11 |
| Education | $77.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $98,435.51 | 2019-2025 | Alhemo |
| Genzyme Corporation | $29,690.04 | 2019-2025 | |
| Novo Nordisk Health Care Ag | $23,635.00 | 2019-2024 | |
| Bioverativ Therapeutics INC. | $23,057.70 | 2019-2020 | |
| Hema Biologics, LLC | $18,721.16 | 2024-2025 | Sevenfact, Sevenfact |
| Sobi, INC | $8,116.96 | 2025 | |
| Genentech USA, INC. | $7,801.79 | 2021-2024 | Hemlibra |
| Kedrion Biopharma, INC. | $7,392.27 | 2025 | Ryplazim, Coagadex, Kedrab |
| Takeda Pharmaceuticals U.S.A., INC. | $4,862.59 | 2020-2025 | Cuvitru, Adynovate |
| Csl Behring | $3,567.13 | 2021-2023 | Idelvion |
| Shire North American Group INC | $2,756.39 | 2019 | |
| F. Hoffmann-La Roche Ag | $2,280.00 | 2022 | |
| Pfizer INC. | $1,849.03 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,290.04 | 2025 | |
| Octapharma USA, INC. | $1,160.38 | 2019-2025 | Nuwiq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Butterfly Network, INC. | $346.15 | 2024 | |
| Bio Products Laboratory USA, INC. | $191.05 | 2019 | |
| Genentech, INC. | $157.04 | 2022-2024 | Hemlibra |
| Uswm, LLC | $103.60 | 2025 | Sevenfact |
| Agios Pharmaceuticals, INC. | $77.97 | 2024 | Pyrukynd |
| Spark Therapeutics, INC. | $11.32 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meera Chitlur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.